IL-33 upregulation is likely to cause an overactive immune response even when no infection is present, hence may be driving autoimmune disease, making it essential to understand its pathway (activation/inhibition) for potential therapeutic intervention in localized scleroderma. This evidence concerns the gene IL33 and localized scleroderma.